30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

DePuy Synthes/JNJ Posts 3Q16 Revenue -

DePuy Synthes posted 3Q16 orthopaedic revenue of US $2,215.0MM, +3.2% vs. 3Q15, as reported. (U.S. $1,343.0MM, +2.4%; ex-U.S. $908.0MM, +4.5%)

ORTHOWORLD estimates 3Q16 segment sales and growth on an as-reported basis, as follows:

  • Joint Reconstruction $789.9MM, +3.7%
    • Hip $328.2MM, +3.3%
    • Knee $363.2MM, +3.4%
    • Extremities Recon $98.5MM, +6.1%
  • Trauma $610.7MM, +4.7%
  • Arthroscopy/Soft Tissue Repair $159.7MM, +2.0%
  • Spine $386.1MM, +2.1%
  • Orthobiologics $97.0MM, +3.6%
  • Other $207.1MM, flat (CMF, Neuro)


In general, for the entire Medical Device segment, leadership cited lower hospital admissions and procedure rates in mid-summer months, with higher levels of activity coming late in the quarter.

As in 2Q, revenue growth was supported externally by overall market health and internally by the Corail primary hip stem, ATTUNE knee and the TFNA nail in the U.S.

DePuy's "Spine & Other" category was impacted by lower inventor levels in 3Q15, partially offset by share loss in Spine.

Price pressure continued across all major categories, partially offset by positive mix in trauma ans spine.

Sources: Johnson & Johnson; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.